Optive Research Introduces Discovery Informatics Solutions Optimized for HP LC-Series Clusters
Optive Research, Inc., an innovative software company providing discovery informatics solutions for the pharmaceutical, agrochemical, and related life science industries, announced certification of their Linux-based Discovery Engine(TM) software products across the HP High Performance Compute Cluster LC series.
Now scientists can access preinstalled and tested computer-assisted drug discovery (CADD) software from Optive on reliable and easy-to-own clusters.
The certification of Optive’s software across the HP LC Series Clusters builds upon the two companies’ previously announced collaboration to provide innovative, scientific solutions for cheminformatics and molecular discovery across HP computing solutions. Companies with a license to Optive’s technology can order the HP Linux-based clusters with Optive’s discovery informatics software preinstalled and configured.
“We are seeing more demand for smaller, departmental Linux clusters which give our users more autonomy when performing computational analyses,” stated Brian Masek, director of Scientific R&D for Optive Research. “Our products are designed to take advantage of parallel computing, and now CADD groups have more options for timely access to the necessary compute power they need to contribute value to discovery and development projects.”
Optive’s complete line of Discovery Engines are now available on the HP LC1000 Series, the LC2000 Series and LC3000 series clusters which feature the HP ProLiant Server running Linux.
“The combination of HP’s LC Series Clusters and Optive’s innovative discovery software provides drug discovery organizations with a high-performance computing solution that can scale to meet their needs,” said Bruce Toal, director of marketing, HP High Performance Technical Computing. “The leader in high-performance technical computing, HP provides a suite of end-to-end HPTC solutions that provide customers increased simplicity, agility and value.”
About Optive Research
Optive Research develops, markets and supports life science software solutions that help companies engaged in molecular discovery research bring beneficial chemical compounds to market faster, while reducing overall cost. Optive’s novel software is designed for both computational chemists and experimental, “wet-lab” scientists, enabling them to reduce discovery cycle times and synthesize higher-quality lead compounds, thereby achieving more predictable discovery processes. Software developed by Optive Research is currently in use at almost every major pharmaceutical company and at hundreds of other research sites worldwide. Further information on Optive Research is available at www.optive.com .
